Named Bioactive Compounds · Compound
Harmaline
Moderate Evidencealkaloid6 PubMed Studies
Hermetica Superfood Encyclopedia
Harmaline is a beta-carboline alkaloid that acts as a potent MAO-A inhibitor with an IC50 of 3-5 nM, potentially supporting mood regulation by increasing serotonin and dopamine levels. This alkaloid also demonstrates vasorelaxant properties through calcium channel modulation and may enhance cognitive function via cholinergic system activation.
Harmaline is a naturally occurring β-carboline alkaloid primarily extracted from Syrian rue (Peganum harmala) seeds native to the Mediterranean and Central Asia, and from Banisteriopsis caapi vines used in South American ayahuasca brews. It is typically extracted using acid-base methods with methanol or ethanol solvents, yielding a crystalline powder with the formula C13H14N2O.
Direct human clinical trials on pure harmaline are limited, with most evidence from a Phase 1 trial of harmine HCl (n=25) showing doses up to 200mg well-tolerated with mild GI/neurological effects (PMID: 39301926). A 90-day rat toxicity study of Thai ayahuasca extract containing harmaline established a NOAEL of 45 mg/kg/day with reversible tremors at higher doses but no organ damage (PMID: 30970283). No large RCTs or meta-analyses exist specifically for harmaline therapeutic outcomes.
Phase 1 human data suggests <2.7 mg/kg single oral dose as potentially safe based on harmine studies. Traditional use involves 3-5g P. harmala seeds (100-200mg harmaline content). Ayahuasca formulations typically deliver 20-60mg total harmala alkaloids per dose. No standardized dosing guidelines exist for isolated harmaline. Consult a healthcare provider before starting any new supplement.
Harmaline (C₁₂H₁₂N₂O; MW 212.25 g/mol) is a dihydro-β-carboline alkaloid, not a nutritional substance per se, but a bioactive compound found naturally in specific plant sources. It has no macronutrient value (no protein, fat, carbohydrate, or fiber contribution at pharmacologically relevant doses). Key details: • Primary natural sources: Seeds of Peganum harmala (Syrian rue) containing ~2–7% total β-carboline alkaloids by dry weight, of which harmaline typically constitutes ~33–56% (approximately 1–4% of seed dry weight); also found in trace amounts in Banisteriopsis caapi vine bark (~0.03–0.08% dry weight, secondary to harmine). • Chemical class: 7-Methoxy-1-methyl-4,9-dihydro-3H-β-carboline; differs from harmine by saturation of the C-3,4 bond in the pyridine ring, resulting in distinct pharmacokinetic and potency profiles. • Bioactive concentration benchmarks: MAO-A inhibition IC₅₀ ~3–5 nM (reversible, competitive); MAO-B inhibition IC₅₀ ~100 µM (highly selective for MAO-A, selectivity ratio ~20,000–30,000-fold); acetylcholinesterase inhibition IC₅₀ ~30–50 µM (moderate). • Bioavailability notes: Oral bioavailability in rodent models estimated at ~20–50% due to significant first-pass hepatic metabolism; primary metabolic pathway is O-demethylation by CYP2D6 and CYP1A2 to harmol and harmalol, followed by glucuronidation and sulfation; plasma half-life approximately 1–3 hours in animal models; crosses the blood-brain barrier readily due to lipophilicity (LogP ~1.6–2.0). • Co-occurring bioactives in P. harmala seeds: Harmine (~2–5% dry weight), harmalol (~0.5–1%), tetrahydroharmine (trace), vasicine/deoxyvasicine (quinazoline alkaloids, ~0.5–1%), plus minor flavonoids and fatty acids in seed oil fraction. • Micronutrient context of whole P. harmala seeds (not harmaline isolate): Seeds contain minerals including potassium, calcium, magnesium, iron, and zinc in modest amounts, plus ~15–20% crude protein, ~10–15% lipid (linoleic and oleic acid predominant), and ~20–25% crude fiber, though these are nutritional properties of the seed matrix rather than harmaline itself. • Solubility: Sparingly soluble in water (~1.5 mg/mL at pH 7); enhanced solubility at acidic pH as hydrochloride salt (~50 mg/mL); freely soluble in ethanol, methanol, and DMSO. • Stability: Sensitive to light (UV degradation of the indole chromophore); relatively stable at acidic pH and under dark storage conditions at room temperature.
Harmaline selectively inhibits monoamine oxidase A (MAO-A) with high potency (IC50 3-5 nM), preventing the breakdown of serotonin, dopamine, and norepinephrine neurotransmitters. The compound activates the cholinergic system by increasing choline acetyltransferase (ChAT) activity more effectively than harmine. Additionally, harmaline induces vasorelaxation through calcium channel blockade and modulation of intracellular calcium signaling pathways.
Research on harmaline is primarily limited to preclinical studies and mechanism-based investigations. Rodent models demonstrate superior cognitive enhancement compared to harmine through increased ChAT activity (PMC5932362). MAO-A inhibition data comes from enzyme assays showing potent inhibitory activity at nanomolar concentrations. Human clinical trials specifically evaluating harmaline's therapeutic effects are lacking, making safety and efficacy profiles in humans largely unknown.
Harmaline carries significant safety concerns due to its potent MAO-A inhibitory activity, which can cause dangerous interactions with tyramine-containing foods and various medications including antidepressants, stimulants, and certain pain medications. The compound may cause hypertensive crises when combined with sympathomimetic drugs or consumed with aged cheeses, fermented foods, or alcoholic beverages. Pregnancy and breastfeeding safety data are unavailable, and the compound should be avoided during these periods. Individuals taking any psychiatric medications should avoid harmaline due to risk of serotonin syndrome.
